tirzepatide onset Time to of AEs in patients receiving Best time to take tirzepatide

Tiredness may occur when starting semaglutide treatment and during upward dose adjustments

We are dedicated to supporting our patients throughout their weight loss journey, helping them achieve and sustain their desired results with patience

According to FDA prescribing information, the most frequently reported adverse reactions include: Gastrointestinal symptoms: Nausea (24-30% of patients) often most pronounced after dose increases Vomiting (8-12% of patients) typically occurs when nausea is severe or unmanaged Diarrhea (18-24% of patients) can range from mild to moderate in severity Constipation (16-17% of patients) paradoxically occurs alongside diarrhea in some individuals Abdominal pain or discomfort (10-14% of patients) often described as cramping or bloating Dyspepsia (6-9% of patients) indigestion, heartburn, or upper abdominal discomfort Gastroesophageal reflux disease (5-7% of patients) Eructation (belching) (5-7% of patients) These symptoms frequently overlap and compound one another

That extra glucagon receptor activation in Retatrutide may contribute to higher energy expenditure and potentially greater fat loss

Tirzepatide is not appropriate for individuals with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)